{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:23:48Z","timestamp":1772846628598,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502239"],"award-info":[{"award-number":["81502239"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The poor prognosis of patients with ovarian cancer is mainly due to cancer progression. \u03b3-Synuclein (SNCG) has reported as a critical player in cancer metastasis. However, its biological roles and mechanism are yet incompletely understood in ovarian cancer, especially in high-grade serous ovarian cancer (HGSOC).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This is a retrospective study of 312 patients with ovarian cancer at a single center between 2006 and 2016. Ovarian cancer tissues were stained by immunohistochemistry to analyze the relationship between SNCG expression and clinicopathologic factors. The clinical outcomes versus SNCG expression level were evaluated by Kaplan\u2013Meier method and multiple Cox regression analysis. Next, systematical functional experiments were given to examine the proliferation and metastatic abilities of SNCG both in vitro and in vivo using loss- and gain- of function approaches. Furthermore, the mechanisms of SNCG overexpression were examined by human phospho-kinase array kit and western blot analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Clinically, the expression of SNCG was significantly upregulated in ovarian cancer compared with the borderline and benign tumor, normal ovary, and fallopian tube. Notably, the high level of SNCG correlated with high-risk clinicopathologic features and showed poor survival for patients with HGSOC, indicating an independent prognostic factor for these patients. Functionally, we observed that overexpression of SNCG promoted cell proliferation, tumor formation, migration, and invasion both in vitro and in vivo. Mechanistically, we identified that SNCG promoted cancer cell metastasis through activating the PI3K\/AKT signaling pathway.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our results reveal SNCG up-regulation contributes to the poor clinical outcome of patients with HGSOC and highlight the metastasis-promoting function of SNCG via activating the PI3K\/Akt signaling pathway in HGSOC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13046-020-01589-9","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:34:54Z","timestamp":1588829694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K\/AKT signaling pathway"],"prefix":"10.1186","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3234-9293","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-xing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"1589_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1159\/000487348","volume":"45","author":"S Cai","year":"2018","unstructured":"Cai S, Zhang P, Dong S, Li L, Cai J, Xu M. Downregulation of SPINK13 promotes metastasis by regulating uPA in ovarian cancer cells. Cell Physiol Biochem. 2018;45:1061\u201371.","journal-title":"Cell Physiol Biochem"},{"key":"1589_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1589_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433\u201343.","journal-title":"Am J Surg Pathol"},{"key":"1589_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","volume":"20","author":"MA Lisio","year":"2019","unstructured":"Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20:952.","journal-title":"Int J Mol Sci"},{"key":"1589_CR5","doi-asserted-by":"crossref","unstructured":"Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;8:CD007565.","DOI":"10.1002\/14651858.CD007565.pub2"},{"key":"1589_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ebiom.2018.11.045","volume":"40","author":"C Rodriguez-Aguayo","year":"2019","unstructured":"Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK\/Erk-ETS1-ELK1\/CFTR1 axis. EBioMedicine. 2019;40:290\u2013304.","journal-title":"EBioMedicine"},{"key":"1589_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1023\/A:1006418219012","volume":"62","author":"J Liu","year":"2000","unstructured":"Liu J, Spence MJ, Zhang YL, Jiang Y, Liu YE, Shi YE. Transcriptional suppression of synuclein gamma (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M. Breast Cancer Res Treat. 2000;62:99\u2013107.","journal-title":"Breast Cancer Res Treat"},{"key":"1589_CR8","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9","volume":"88","author":"W Bruening","year":"2000","unstructured":"Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer. 2000;88:2154\u201363.","journal-title":"Cancer"},{"key":"1589_CR9","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/cncr.30477","volume":"123","author":"AD Winder","year":"2017","unstructured":"Winder AD, Maniar KP, Wei JJ, Liu D, Scholtens DM, Lurain JR, et al. Synuclein-gamma in uterine serous carcinoma impacts survival: an NRG oncology\/gynecologic oncology group study. Cancer. 2017;123:1144\u201355.","journal-title":"Cancer"},{"key":"1589_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41419-018-0657-z","volume":"9","author":"T Shao","year":"2018","unstructured":"Shao T, Song P, Hua H, Zhang H, Sun X, Kong Q, et al. Gamma synuclein is a novel Twist1 target that promotes TGF-beta-induced cancer cell migration and invasion. Cell Death Dis. 2018;9:625.","journal-title":"Cell Death Dis"},{"key":"1589_CR11","doi-asserted-by":"publisher","first-page":"27435","DOI":"10.18632\/oncotarget.25415","volume":"9","author":"L Tian","year":"2018","unstructured":"Tian L, Zhao Y, Truong MJ, Lagadec C, Bourette RP. Synuclein gamma expression enhances radiation resistance of breast cancer cells. Oncotarget. 2018;9:27435\u201347.","journal-title":"Oncotarget"},{"key":"1589_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000488571","volume":"154","author":"C Fan","year":"2018","unstructured":"Fan C, Liu J, Tian J, Zhang Y, Yan M, Zhu C. siRNA targeting of the SNCG gene inhibits the growth of gastric carcinoma SGC7901 cells in vitro and in vivo by downregulating the phosphorylation of AKT\/ERK. Cytogenet Genome Res. 2018;154:209\u201316.","journal-title":"Cytogenet Genome Res"},{"key":"1589_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13048-016-0281-4","volume":"9","author":"A Strohl","year":"2016","unstructured":"Strohl A, Mori K, Akers S, Bshara W, Buttin B, Frederick PJ, et al. Synuclein-gamma (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. J Ovarian Res. 2016;9:75.","journal-title":"J Ovarian Res"},{"key":"1589_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ijc.26364","volume":"131","author":"T Fekete","year":"2012","unstructured":"Fekete T, Raso E, Pete I, Tegze B, Liko I, Munkacsy G, et al. Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int J Cancer. 2012;131:95\u2013105.","journal-title":"Int J Cancer"},{"key":"1589_CR15","first-page":"1201","volume":"29","author":"ZZ Pan","year":"2006","unstructured":"Pan ZZ, Bruening W, Godwin AK. Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. Int J Oncol. 2006;29:1201\u20135.","journal-title":"Int J Oncol"},{"key":"1589_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.humpath.2015.05.015","volume":"46","author":"J Zhang","year":"2015","unstructured":"Zhang J, Tang L, Chen Y, Duan Z, Xiao L, Li W, et al. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer. Hum Pathol. 2015;46:1331\u201340.","journal-title":"Hum Pathol"},{"key":"1589_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.biochi.2019.08.003","volume":"165","author":"M Karimi Roshan","year":"2019","unstructured":"Karimi Roshan M, Soltani A, Soleimani A, Rezaie Kahkhaie K, Afshari AR, Soukhtanloo M. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie. 2019;165:229\u201334.","journal-title":"Biochimie"},{"key":"1589_CR18","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-07-6302","volume":"68","author":"YL Pon","year":"2008","unstructured":"Pon YL, Zhou HY, Cheung AN, Ngan HY, Wong AS. p70S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res. 2008;68:6524\u201332.","journal-title":"Cancer Res"},{"key":"1589_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s11658-019-0172-y","volume":"24","author":"C Zhang","year":"2019","unstructured":"Zhang C, Gu L, Li X, Wang J. Silencing of Synuclein-gamma inhibits human cervical cancer through the AKT signaling pathway. Cell Mol Biol Lett. 2019;24:49.","journal-title":"Cell Mol Biol Lett"},{"key":"1589_CR20","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/onc.2014.126","volume":"34","author":"W Liang","year":"2015","unstructured":"Liang W, Miao S, Zhang B, He S, Shou C, Manivel P, et al. Synuclein gamma protects Akt and mTOR and renders tumor resistance to Hsp90 disruption. Oncogene. 2015;34:2398\u2013405.","journal-title":"Oncogene"},{"key":"1589_CR21","doi-asserted-by":"publisher","unstructured":"Kessous R, Wissing MD, Piedimonte S, Abitbol J, Kogan L, Laskov I, Yasmeen A, Salvador S, Lau S, Gotlieb WH. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer. Acta Obstet Gynecol Scand. 2020;18. https:\/\/doi.org\/10.1111\/aogs.13814.","DOI":"10.1111\/aogs.13814"},{"key":"1589_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","volume":"23","author":"JD Seidman","year":"2004","unstructured":"Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41\u20134.","journal-title":"Int J Gynecol Pathol"},{"key":"1589_CR23","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1634\/theoncologist.2019-0497","volume":"24","author":"E Lou","year":"2019","unstructured":"Lou E, Vogel RI, Hoostal S, Wong P, Grad A, Monu M, et al. Analysis of differentially expressed MicroRNAs and circulating tumor cells as predictive biomarkers of platinum Chemoresistance in primary ovarian carcinomas: a prospective study. Oncologist. 2019;24:1422\u2013e1013.","journal-title":"Oncologist"},{"key":"1589_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/molehr\/gan056","volume":"14","author":"MN Singh","year":"2008","unstructured":"Singh MN, Stringfellow HF, Taylor SE, Ashton KM, Ahmad M, Abdo KR, et al. Elevated expression of CYP1A1 and gamma-SYNUCLEIN in human ectopic (ovarian) endometriosis compared with eutopic endometrium. Mol Hum Reprod. 2008;14:655\u201363.","journal-title":"Mol Hum Reprod"},{"key":"1589_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ygyno.2011.09.037","volume":"124","author":"P Mhawech-Fauceglia","year":"2012","unstructured":"Mhawech-Fauceglia P, Wang D, Syriac S, Godoy H, Dupont N, Liu S, et al. Synuclein-gamma (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma. Gynecol Oncol. 2012;124:148\u201352.","journal-title":"Gynecol Oncol"},{"key":"1589_CR26","doi-asserted-by":"publisher","first-page":"35050","DOI":"10.1074\/jbc.M201650200","volume":"277","author":"ZZ Pan","year":"2002","unstructured":"Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem. 2002;277:35050\u201360.","journal-title":"J Biol Chem"},{"key":"1589_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.9734\/BJMMR\/2011\/769","volume":"1","author":"KT Cheung","year":"2011","unstructured":"Cheung KT, Taylor SE, Patel AJ II, Bentley HF, Stringfellow NJF, Martin-Hirsch PL, et al. Expression of ERalpha, its ERalphaDelta3 splice variant and gamma-SYNUCLEIN in ovarian cancer: a pilot study. Br J Med Med Res. 2011;1:430\u201344.","journal-title":"Br J Med Med Res"},{"key":"1589_CR28","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/ijc.22763","volume":"121","author":"J Guo","year":"2007","unstructured":"Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L, et al. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer. 2007;121:1296\u2013305.","journal-title":"Int J Cancer"},{"key":"1589_CR29","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.3892\/etm.2016.3838","volume":"12","author":"L Wang","year":"2016","unstructured":"Wang L, Gao H, Gong N, Gong M. Downregulation of microRNA-497 is associated with upregulation of synuclein gamma in patients with osteosarcoma. Exp Ther Med. 2016;12:3761\u20136.","journal-title":"Exp Ther Med"},{"key":"1589_CR30","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1111\/febs.13055","volume":"281","author":"C Liu","year":"2014","unstructured":"Liu C, Qu L, Lian S, Tian Z, Zhao C, Meng L, et al. Unconventional secretion of synuclein-gamma promotes tumor cell invasion. FEBS J. 2014;281:5159\u201371.","journal-title":"FEBS J"},{"key":"1589_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0022034515621728","volume":"95","author":"JC Cheng","year":"2016","unstructured":"Cheng JC, Chiang MT, Lee CH, Liu SY, Chiu KC, Chou YT, et al. Gamma-Synuclein expression is a malignant index in Oral squamous cell carcinoma. J Dent Res. 2016;95:439\u201345.","journal-title":"J Dent Res"},{"key":"1589_CR32","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.18632\/oncotarget.14276","volume":"8","author":"X He","year":"2017","unstructured":"He X, Zheng Y, Zhang Y, Gan Y, Zhou Y, Liang H, et al. Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of gamma-synuclein in hepatocellular carcinoma cells. Oncotarget. 2017;8:9451\u201365.","journal-title":"Oncotarget"},{"key":"1589_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","volume":"59","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani AS. PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125\u201332.","journal-title":"Semin Cancer Biol"},{"key":"1589_CR34","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.7150\/thno.33972","volume":"9","author":"DJ Lv","year":"2019","unstructured":"Lv DJ, Song XL, Huang B, Yu YZ, Shu FP, Wang C, et al. HMGB1 promotes prostate cancer development and metastasis by interacting with Brahma-related gene 1 and activating the Akt signaling pathway. Theranostics. 2019;9:5166\u201382.","journal-title":"Theranostics"},{"key":"1589_CR35","doi-asserted-by":"publisher","first-page":"11959","DOI":"10.1096\/fj.201802416RR","volume":"33","author":"Y Liu","year":"2019","unstructured":"Liu Y, Liu Q, Chen S, Liu Y, Huang Y, Chen P, et al. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling. FASEB J. 2019;33:11959\u201372.","journal-title":"FASEB J"},{"key":"1589_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/cancers12010205","volume":"12","author":"M Sobocan","year":"2020","unstructured":"Sobocan M, Bracic S, Knez J, Takac I, Haybaeck J. The communication between the PI3K\/AKT\/mTOR pathway and Y-box binding Protein-1 in gynecological cancer. Cancers (Basel). 2020;12:205.","journal-title":"Cancers (Basel)"}],"updated-by":[{"DOI":"10.1186\/s13046-020-01596-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-020-01589-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T23:39:41Z","timestamp":1620344381000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-020-01589-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1186\/s13046-020-01589-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13046-020-01596-w","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"18 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the First Affiliated Hospital of Chongqing Medical University. All animal procedures were approved by the Institution Animal Care Committee at Chongqing Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}